智通财经7月30日晚间新闻精选 3、百亿湖北人形机器人母基金启动，首期50亿落地，前瞻布局机器人"大脑"和"小脑"及"肢体"等领 域。 1、中共中央政治局召开会议，决定召开二十届四中全会，分析研究当前经济形势和经济工作。会议指 出，宏观政策要持续发力、适时加力；增强国内资本市场的吸引力和包容性，巩固资本市场回稳向好势 头。 2、中央财政今年初步安排预算900亿元育儿补贴，各地将在8月下旬陆续开放育儿补贴申领。 4、广期所调整工业硅、多晶硅、碳酸锂期货部分合约交易限额，部分合约单日开仓量不得超过500手。 5、宁德时代上半年实现净利润305亿元 同比增长33.02%。上纬新材：多次触及股票交易异常波动和严 重异常波动情形 明起停牌核查。南新制药：近期正筹划购买某一国内药品技术等资产组事项 尚无法确 定是否构成重大资产重组。20CM五天四板幸福蓝海：公司是《南京照相馆》的投资方之一 投资比例较 低。2连板阳光乳业：公司控股股东近两日合计卖出114.52万股。 ...

（原标题：7月30日重要资讯一览） 重要的消息有哪些 1．中共中央政治局7月30日召开会议，会议指出，要持续防范化解重点领域风险。落实好中央城市工作会议精神，高质量开展城市更新。积极稳 妥化解地方政府债务风险，严禁新增隐性债务，有力有序有效推进地方融资平台出清。增强国内资本市场的吸引力和包容性，巩固资本市场回稳 向好势头。 2．财政部社会保障司司长郭阳7月30日在国新办新闻发布会上表示，中央财政将设立共同财政事权转移支付项目"育儿补贴补助资金"，今年初步 安排预算900亿元左右。对于发放国家基础标准补贴所需资金，中央财政按照一定比例对地方予以补助，中央财政总体承担90%。 3．7月30日，外交部发言人郭嘉昆主持例行记者会。在回答有关中美经贸会谈的问题时，郭嘉昆表示，关于此次中美经贸会谈的情况，中方已经 发布了消息。我们希望美方同中方一道，按照两国元首通话达成的重要共识，发挥好中美经贸磋商机制的作用，在平等、尊重、互惠基础上，通 过对话沟通，增进共识、减少误解、加强合作，争取更多双赢成果，共同推动中美关系健康稳定可持续发展。 4．国家发改委向社会公开征求《政府投资基金布局规划和投向工作指引》和《加强政府投资基金 ...

Important Announcements - Company Shouwei New Materials will suspend trading for inspection on July 31, 2025, due to abnormal stock price fluctuations from July 9 to July 30, 2025 [2] - Company XGIMI Technology expects a net profit attributable to shareholders of 88.66 million yuan for the first half of the year, a year-on-year increase of 2062.33% [4] - Company Yuntian Lifei has submitted an application for H-share issuance and listing [5] - Company Huaheng Biological is planning to issue H-shares and list on the Hong Kong Stock Exchange [6] - Company Hehua Co., Ltd. is planning a change in control, leading to a suspension of trading [10] Financial Performance - Company Dingtong Technology reported a net profit of 115 million yuan for the first half of the year, a year-on-year increase of 134.06%, with a proposed cash dividend of 2 yuan per 10 shares [7] - Company Jinhai Biological achieved a net profit of 138 million yuan in the first half of the year, a year-on-year increase of 51.52% [13] - Company Hisense Home Appliances reported a net profit of 2.077 billion yuan for the first half of the year, a year-on-year increase of 3.01% [14] Corporate Actions - Company Nanxin Pharmaceutical is planning to acquire a domestic pharmaceutical technology asset group, but there is significant uncertainty regarding the completion of this acquisition [3] - Company Jinchengzi is planning to acquire 55% of the shares of Changchun Samit Optoelectronics Technology Co., Ltd., leading to a suspension of trading [9] - Company San Chao New Materials is also planning a change in control, resulting in a trading suspension [11] Project Investments - Company Changjiang Electric Power plans to invest approximately 26.6 billion yuan in the construction of the Gezhouba Navigation Capacity Expansion Project [8]

Group 1: Company Announcements - Upwind New Materials will suspend trading for stock review starting July 31, 2025, due to abnormal price fluctuations from July 9 to July 30, 2025 [2] - XGIMI Technology expects a net profit attributable to shareholders of 88.66 million yuan for the first half of 2025, a year-on-year increase of 2062.33% [4] - CloudWalk Technology has submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [5] - Huaheng Biological is planning to issue H-shares and list on the Hong Kong Stock Exchange [6] - Hehua Co., Ltd. is undergoing a control change process, leading to a stock suspension starting July 31, 2025 [9] Group 2: Financial Performance - DingTong Technology reported a net profit of 115 million yuan for the first half of 2025, a year-on-year increase of 134.06%, with a proposed cash dividend of 2 yuan per 10 shares [7] - Jinhe Biological achieved a net profit of 138 million yuan in the first half of 2025, a year-on-year increase of 51.52% [12] - Hisense Home Appliances reported a net profit of 2.077 billion yuan for the first half of 2025, a year-on-year increase of 3.01% [13] Group 3: Corporate Developments - Nanxin Pharmaceutical is planning to acquire a domestic pharmaceutical technology asset group, but there is significant uncertainty regarding the completion of this acquisition [3] - Jinchengzi is planning to acquire 55% of the equity of Changchun Samit Optoelectronics Technology Co., Ltd., leading to a stock suspension starting July 31, 2025 [8] - SanChao New Materials is also planning a control change, resulting in a stock suspension starting July 31, 2025 [10] Group 4: Industry Developments - Changjiang Electric Power plans to invest approximately 26.6 billion yuan in the construction of the Gezhouba Navigation Capacity Expansion Project, with a total construction period of 91 months [8] - Yonghui Supermarket intends to raise no more than 3.992 billion yuan through a private placement to upgrade stores and logistics [8]

Group 1 - Company Shenzhou New Materials has experienced multiple instances of abnormal stock trading fluctuations and will be suspended from trading starting July 31, 2025, for up to three trading days [1] - The stock price of Shenzhou New Materials has increased over 1288% this year, making it the first tenfold stock of 2025 [1] - Company Yangtze Power plans to invest approximately 26.6 billion yuan in the construction of the Gezhouba shipping capacity expansion project, with funding sourced from its own funds [2] - Yonghui Supermarket intends to raise no more than 3.992 billion yuan through a private placement of A-shares for store upgrades and logistics improvements [3] Group 2 - Chipsea Technology is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its international strategy and competitiveness [4] - Zhongwang Software is facing a copyright infringement lawsuit from Autodesk in a California federal court, with the amount in dispute yet to be determined [5] - Jinchengzi is planning to acquire 55% of the equity of Changchun Samit Optoelectronics Technology Co., Ltd., and will suspend trading starting July 31, 2025, for up to ten trading days [6] - Nanxin Pharmaceutical is in the process of planning the acquisition of a domestic pharmaceutical technology asset group, with significant uncertainty regarding whether it constitutes a major asset restructuring [7] Group 3 - Huaheng Biological is preparing to issue H-shares and list on the Hong Kong Stock Exchange to advance its global strategy [9] - Sanchao New Materials is planning a change in company control and will suspend trading starting July 31, 2025, for up to two trading days [10] - Digital Certification's controlling shareholder will change to Beijing Data Group following a transfer of state-owned shares [11] - Hongxiang Co., Ltd.'s actual controller has been placed under residential surveillance, but this will not affect the company's normal operations [12]

公告显示，南新制药股票交易连续三个交易日内（7月28日—30日）收盘价格涨幅偏离值累计达到 30%，根据《上海证券交易所交易规则》《上海证券交易所科创板股票异常交易实时监控细则》的有关 规定，属于股票交易异常波动的情形。7月30日，南新制药收涨20%，收盘价为14.28元/股。 北京商报讯（记者 丁宁）7月30日晚间，南新制药（688189）发布公告称，公司近期正在筹划购买某一 国内药品技术等资产组事项，尚无法确定是否构成重大资产重组。该事项正处于筹划阶段，尚未签署任 何有关收购的意向协议，是否能够顺利实施存在重大不确定性。公司将根据该事项的进展情况及时履行 信息披露义务，具体内容以公司后续公告为准。 ...

7月30日南新制药(688189)收盘价14.28元，收盘涨停，全天换手率18.41%，振幅20.00%，成交额6.93亿 元。科创板交易公开信息显示，当日该股因日收盘价涨幅达15%等上榜。 南新制药7月30日龙虎榜 | 买入营业部名称 | 买入金额(万元) | | --- | --- | | 国泰海通证券股份有限公司总部 | 1943.58 | | 中信建投证券股份有限公司北京朝阳分公司 | 1637.53 | | 华泰证券股份有限公司总部 | 1519.17 | | 华鑫证券有限责任公司绍兴胜利东路证券营业部 | 1319.76 | | 中国中金财富证券有限公司杭州江河汇证券营业部 | 1234.99 | | 卖出营业部名称 | 卖出金额(万元) | | 国泰海通证券股份有限公司总部 | 1878.45 | | 东方财富证券股份有限公司上海东方路证券营业部 | 1253.83 | | 机构专用 | 1096.71 | | 瑞银证券有限责任公司上海花园石桥路证券营业部 | 1000.09 | | 国金证券股份有限公司上海静安区南京西路证券营业部 | 936.91 | 证券时报·数据宝统计显示，上榜的前五大买 ...

每经AI快讯，有投资者在投资者互动平台提问：公司有什么产品可以用于治疗基孔肯雅热病症吗？ 南新制药（688189.SH）7月30日在投资者互动平台表示，公司暂未生产和销售治疗该病症的药品。 （文章来源：每日经济新闻） ...

证券代码：688189 证券简称：南新制药 公告编号：2025-029 湖南南新制药股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 1、湖南南新制药股份有限公司（以下简称"公司"）股票交易连续三个交易 日内（2025 年 7 月 28 日、7 月 29 日和 7 月 30 日）收盘价格涨幅偏离值累计达 到 30%，根据《上海证券交易所交易规则》《上海证券交易所科创板股票异常交 易实时监控细则》的有关规定，属于股票交易异常波动的情形。 2、公司近期正在筹划购买某一国内药品技术等资产组事项（以下简称"本 次交易"），尚无法确定是否构成重大资产重组。该事项正处于筹划阶段，尚未签 署任何有关收购的意向协议，是否能够顺利实施存在重大不确定性。公司将根据 该事项的进展情况及时履行信息披露义务，具体内容以公司后续公告为准。敬请 广大投资者理性投资，注意风险。 （一）生产经营情况 3、经公司自查，并向控股股东书面发函查证，公司日常经营情况正常，未 发生重大变化，市场环境或行业政策未发生重大 ...

人民财讯7月30日电，南新制药(688189)7月30日晚间发布股票交易异常波动公告称，近期正在筹划购买 某一国内药品技术等资产组事项，尚无法确定是否构成重大资产重组。该事项正处于筹划阶段，尚未签 署任何有关收购的意向协议，是否能够顺利实施存在重大不确定性。敬请广大投资者理性投资，注意风 险。 ...